/NNNN

NNNN Stock - Anbio Biotechnology Class A Ordinary Shares

Q: What is the analyst price target for NNNN?

Analyst price target information is not currently available for NNNN.

Q: What is NNNN's market cap?

Market capitalization information is not currently available for NNNN.

Healthcare|Medical - Instruments & Supplies|NASDAQ

$32.35+6.94%

+$2.10 (+6.94%) • Dec 19

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $35.59

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for NNNN

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2021

FY2022

FY2023

FY2024

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta1.80

52W High$55.65

52W Low$5.18

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2024	FY2023	FY2022	FY2021
Revenue	$8.19M	$6.71M	$23.54M	$4.43M
Gross Profit	$5.89M	$3.36M	$12.56M	$2.54M
Gross Margin	71.9%	50.1%	53.4%	57.4%
Operating Income	$2.00M	$1.96M	$10.20M	$2.46M
Net Income	$2.37M	$2.25M	$10.01M	$2.54M
Net Margin	29.0%	33.6%	42.5%	57.3%
EPS	$0.06	$0.02	$0.07	$0.03

Company Overview

Anbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, Africa, and internationally. It offers SARS-CoV-2 antigen rapid and SARS-CoV-2/influenza A/B antigen rapid tests; and lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification, chemiluminescence immunoassay, and reverse-transcription polymerase chain reaction products. It serves over-the-counter, point-of-care testing, and laboratory markets. The company was incorporated in 2021 and is based in Frankfurt am Main, Germany.

Visit Website

Frequently Asked Questions about NNNN

What is NNNN's current stock price?

Anbio Biotechnology Class A Ordinary Shares (NNNN) is currently trading at $32.35 per share. The stock has moved +6.94% today.

What is the analyst price target for NNNN?

No analyst price targets are currently available for this stock.

What sector is Anbio Biotechnology Class A Ordinary Shares in?

Anbio Biotechnology Class A Ordinary Shares operates in the Healthcare sector, specifically within the Medical - Instruments & Supplies industry. The company is traded on the NASDAQ exchange.

What is NNNN's market cap?

Anbio Biotechnology Class A Ordinary Shares has a market capitalization of $1.42 billion, making it a small-cap company.

Does NNNN pay dividends?

No, Anbio Biotechnology Class A Ordinary Shares does not currently pay a dividend to shareholders.